Compare ARKR & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARKR | INTS |
|---|---|---|
| Founded | 1983 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.0M | 24.0M |
| IPO Year | N/A | 2023 |
| Metric | ARKR | INTS |
|---|---|---|
| Price | $6.40 | $0.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.33 |
| AVG Volume (30 Days) | 19.2K | ★ 3.1M |
| Earning Date | 12-15-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $165,751,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.75 | $0.19 |
| 52 Week High | $17.76 | $3.17 |
| Indicator | ARKR | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 39.20 | 45.52 |
| Support Level | $5.98 | $0.37 |
| Resistance Level | $6.73 | $0.43 |
| Average True Range (ATR) | 0.37 | 0.05 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 43.97 | 13.19 |
Ark Restaurants Corp owns and operates around 17 restaurants and bars, 16 fast food concepts, and catering operations in the USA. The Las Vegas operations include New York Hotel & Casino Resort, hotel room service operations, banquet facilities, employee dining room, food court concepts, and a restaurant within the Planet Hollywood Resort and Casino. It operates a restaurant and a bar in the Resorts Atlantic City Hotel and Casino and a restaurant in the Tropicana Hotel and Casino. The Florida operations include The Rustic Inn in Dania Beach, Shuckers in Jensen Beach, JB's on the Beach in Deerfield Beach, The Blue Moon Fish Company in Fort Lauderdale, and fast food facilities in Tampa and Hollywood. In Alabama, it operates Original Oyster Houses in Gulf Shores and Spanish Fort.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.